Stakeholders Consider Impact of BBBA Drug Pricing Reforms on Formularies, Innovation

The Build Back Better Act (BBBA), which passed the House on Nov. 19 but at press time was looking less and less likely to meet Democrats’ self-imposed Christmas deadline, contains multiple drug pricing reforms that could lead to more than $300 billion in savings over the next decade, according to estimates from the Congressional Budget Office (CBO). These provisions include an overhaul of the Medicare D benefit, which a recent Avalere Health analysis suggests could lead to greater increases in mandatory manufacturer discounts on brand drugs within the benefit’s six “protected classes” compared with brand Part D drugs overall.

© 2022 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

chemist-looking-through-a-microscope-working-with-his-colleagues-on-antiviral-drug-in-a-laboratory
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
united-states-capitol-building
November 5

For Managed Care, Democrats’ Spending Bill Is Mixed Bag

READ MORE
post-default-image
March 4

Likelihood of Part D Revamp Increases With COVID Relief Bill

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today